PRESENTATION · Dec 2024 · PDF

BBIO - Acoramidis - ISA 2024 - Rationale & design of ACT-EARLY

PRESENTATION · Dec 2024 · PDF

Acoramidis - ISA 2024- Featured research in the ATTR-CM landscape

PRESENTATION · Dec 2024 · PDF

BBIO - Acoramidis - ESC Heart Failure 2024 - EQ-5D Analysis from the ATTRibute-CM Study

PRESENTATION · Dec 2024 · PDF

BBIO - Acoramidis - ESC Heart Failure 2024 - NT-proBNP Insights from the ATTRibute-CM Study

PUBLICATION · Dec 2024 · PDF

Circulation: Heart Failure, Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy

PRESENTATION · Dec 2024 · PDF

BBIO - Acoramidis - ESC Heart Failure 2024 - Improved Health-Related Quality of Life in Acoramidis-Treated Patients with ATTR-CM, Demonstrated by Improvements in KCCQ Scores

PRESENTATION · Nov 2024 · PDF

BBIO - Acoramidis - ESC Heart Failure 2024 - ITT Sensitivity Analysis and Sub-Analysis Comparing Acoramidis and Placebo in Stage 4 CKD in ATTRibute-CM

PRESENTATION · Nov 2024 · PDF

BBIO - Acoramidis - ACC 2024 - CMR Imaging Substudy from ATTRibute-CM Phase 3 Study

PUBLICATION · Jun 2024 · PDF

Journal of Bone and Mineral Research, Infigratinib Low Dose Therapy Is an Effective Strategy to Treat Hypochondroplasia

PUBLICATION · Mar 2024 · PDF

Journal of Muscle Research and Cell Motility, Validation of a Novel Western Blot Assay to Monitor Patterns and Levels of Alpha Dystroglycan in Skeletal Muscle of Patients with Limb-girdle Muscular Dystrophies